Karimi O - Search Results

1

JAK2 V617F mutation is not involved in thromboembolism in IBD.

Karimi O, Crusius JB, Coucoutsi C, Heijmans R, Sambuelli AM, Peña AS, Koutroubakis IE. Karimi O, et al. Inflamm Bowel Dis. 2008 Nov;14(11):1606-7. doi: 10.1002/ibd.20471. Inflamm Bowel Dis. 2008. PMID: 18398895 No abstract available.

2

Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease.

Shrestha UK, Karimi O, Crusius JB, Zhou F, Wang Z, Chen Z, van Bodegraven AA, Xiao J, Morré SA, Wang H, Li J, Xia B. Shrestha UK, et al. Among authors: karimi o. Inflamm Bowel Dis. 2010 Feb;16(2):312-9. doi: 10.1002/ibd.21059. Inflamm Bowel Dis. 2010. PMID: 19714744

3

Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study.

Karimi O, Peña AS, van Bodegraven AA. Karimi O, et al. Drugs Today (Barc). 2005 Jul;41(7):453-9. doi: 10.1358/dot.2005.41.7.917341. Drugs Today (Barc). 2005. PMID: 16193098 Clinical Trial.

4

Indications and challenges of probiotics, prebiotics, and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease.

Karimi O, Peña AS. Karimi O, et al. J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S136-41. doi: 10.1097/MCG.0b013e3181662455. J Clin Gastroenterol. 2008. PMID: 18806706 Review.

5

Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary.

Karimi O, Peña AS. Karimi O, et al. Rev Esp Enferm Dig. 2005 Aug;97(8):570-4. doi: 10.4321/s1130-01082005000800005. Rev Esp Enferm Dig. 2005. PMID: 16266224 Free article. Review.

6

Probiotics: Isolated bacteria strain or mixtures of different strains? Two different approaches in the use of probiotics as therapeutics.

Karimi O, Pena AS. Karimi O, et al. Drugs Today (Barc). 2003 Aug;39(8):565-97. doi: 10.1358/dot.2003.39.8.799406. Drugs Today (Barc). 2003. PMID: 14566382 Review.

7

A new avenue to investigate: the autophagic process. From Crohn's disease to Chlamydia.

Peña AS, Karimi O, Crusius JB. Peña AS, et al. Among authors: karimi o. Drugs Today (Barc). 2009 Nov;45 Suppl B:113-7. Drugs Today (Barc). 2009. PMID: 20011702 Review.

8

TLR2 haplotypes in the susceptibility to and severity of Chlamydia trachomatis infections in Dutch women.

Karimi O, Ouburg S, de Vries HJ, Peña AS, Pleijster J, Land JA, Morré SA. Karimi O, et al. Drugs Today (Barc). 2009 Nov;45 Suppl B:67-74. Drugs Today (Barc). 2009. PMID: 20011697

9

TLR2, TLR4 and TLR9 genotypes and haplotypes in the susceptibility to and clinical course of Chlamydia trachomatis infections in Dutch women.

Verweij SP, Karimi O, Pleijster J, Lyons JM, de Vries HJ, Land JA, Morré SA, Ouburg S. Verweij SP, et al. Among authors: karimi o. Pathog Dis. 2016 Feb;74(1):ftv107. doi: 10.1093/femspd/ftv107. Epub 2015 Nov 13. Pathog Dis. 2016. PMID: 26568059 Free PMC article.

10

Chlamydia trachomatis: identification of susceptibility markers for ocular and sexually transmitted infection by immunogenetics.

Morré SA, Karimi O, Ouburg S. Morré SA, et al. Among authors: karimi o. FEMS Immunol Med Microbiol. 2009 Mar;55(2):140-53. doi: 10.1111/j.1574-695X.2009.00536.x. Epub 2009 Jan 26. FEMS Immunol Med Microbiol. 2009. PMID: 19170753 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page